Septerna, Inc. (SEPN)
NASDAQ:SEPN
SEPN Stock Chart & Stats
$24.03
$0.38(1.86%)
At close: 4:00 PM EST
$24.03
$0.38(1.86%)
Day’s Range― - ―
52-Week Range$4.66 - $32.63
Previous CloseN/A
Volume49.14K
Average Volume (3M)314.11K
Market Cap
$1.08B
Enterprise Value$982.00M
Total Cash (Recent Filing)$391.09M
Total Debt (Recent Filing)$23.63M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
May 14, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding44,906,376
10 Day Avg. Volume240,766
30 Day Avg. Volume314,105
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)3.23
Price to Sales (P/S)26.85
P/FCF Ratio11.25
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue21.37
Enterprise Value/Gross Profit21.37
Enterprise Value/Ebitda-12.40
Forecast
1Y Price Target
$40.25Price Target Upside67.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.64
Revenue Forecast (FY)$68.30M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPositive Phase 1 results for SEP-631 demonstrated clear clinical proof of mechanism and supported advancement into a randomized, double-blind, placebo-controlled Phase 2b trial in chronic spontaneous urticaria.
Mechanism Of ActionSEP-631 locks the MRGPRX2 receptor with durable inhibition and slow dissociation, suggesting potential superiority as an oral inhibitor across multiple mast cell–driven diseases beyond chronic spontaneous urticaria.
Pipeline ExpansionSEP-479 completed investigational new drug enabling studies with supportive preclinical pharmacology and a projected human profile that supports once-daily oral dosing, while the TSHR program is progressing toward lead candidate selection to broaden the clinical pipeline.
Bears Say
Clinical Evidence LimitationsAvailable clinical data are derived from healthy volunteer challenge studies, leaving effectiveness in patients with the target diseases unproven and uncertain.
Financial OutlookPartner payments support a multiyear runway, but operating expenses are expected to increase and net losses are projected to widen, creating risk to long-term financial stability if further funding is needed.
Safety Uncertainty In PatientsSafety and tolerability outcomes observed in healthy volunteers may not predict patient safety, requiring additional patient data to confirm the absence of treatment-emergent adverse effects in disease populations.
Septerna, Inc. News
SEPN FAQ
What was Septerna, Inc.’s price range in the past 12 months?
Septerna, Inc. lowest stock price was $4.66 and its highest was $32.63 in the past 12 months.
What is Septerna, Inc.’s market cap?
Septerna, Inc.’s market cap is $1.08B.
When is Septerna, Inc.’s upcoming earnings report date?
Septerna, Inc.’s upcoming earnings report date is May 14, 2026 which is in 43 days.
How were Septerna, Inc.’s earnings last quarter?
Septerna, Inc. released its earnings results on Mar 26, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.254 by $0.014.
Is Septerna, Inc. overvalued?
According to Wall Street analysts Septerna, Inc.’s price is currently Undervalued.
Does Septerna, Inc. pay dividends?
Septerna, Inc. does not currently pay dividends.
What is Septerna, Inc.’s EPS estimate?
Septerna, Inc.’s EPS estimate is -0.35.
How many shares outstanding does Septerna, Inc. have?
Septerna, Inc. has 44,906,376 shares outstanding.
What happened to Septerna, Inc.’s price movement after its last earnings report?
Septerna, Inc. reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.254. Following the earnings report the stock price went down -3.517%.
Which hedge fund is a major shareholder of Septerna, Inc.?
Currently, no hedge funds are holding shares in SEPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Septerna, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.25 (67.50% Upside)
$40.25 (67.50% Upside)
Blogger Sentiment
Bullish
SEPN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 439.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 9.1%
Last 30 Days ▲ 9.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
281.96%
12-Months-Change
Fundamentals
Return on Equity
-12.63%
Trailing 12-Months
Asset Growth
31.85%
Trailing 12-Months
Company Description
Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
SEPN Stock 12 Month Forecast
Average Price Target
$40.25
▲(67.50% Upside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
Day One Biopharmaceuticals
―
Ownership Overview
Currently, No data available
---